1. New Insights Into Neurogenic Orthostatic Hypotension

2. Typical Non-neurologic Causes of Orthostatic Hypotension

3. Primary Causes of Neurogenic Orthostatic Hypotension

4. Neurogenic Orthostatic Hypotension Clinical Phenotypes

5. Neurotransmitter Disorders

6. Differences Between nOH and Non-neurogenic OH

7. Nocturnal Hypertension is a Common Problem in nOH Patient Populations

8. Pronounced Blood Pressure Variability

9. Factors That Exacerbate OH and nOH

10. Concerns and Comorbidities in nOH Patients, Particularly With Advanced Disease

11. Common Treatment Options for nOH

12. Droxidopa vs Levodopa

13. Pivotal Study 301 Key Inclusion and Exclusion Criteria

14. Orthostatic Hypotension Questionnaire (OHQ)

15. Study Design Droxidopa Pivotal Trial 301

16. Study 301 OHQ Composite After 1 Week

17. Dizziness/Lightheadedness (Item 1 on the Questionnaire)

18. Study 301 (cont) Increase in Standing BP

19. Doxidropa Study in Parkinson’s Disease Inclusion and Exclusion Criteria

20. Study Design

21. Study 306 in Patients With PD and nOH: Primary Outcome Measure: Dizziness/Lightheadedness

22. Increases in Standing Blood Pressure

23. Cardiovascular Disorders in Droxidopa Studies

24. Evaluation of Deaths in Droxidopa Studies (Including Long-term Safety Extensions)

25. Rates of Nonfatal Cardiovascular Serious Events Across All Studies

26. Falls Related to Doxidropa vs Placebo

27. Droxidopa Clinical Management of Supine Hypertension

28. Key Points in Using Droxidopa* for Neurogenic Hypotension

29. Abbreviations

30. References

31. References (cont)